Search Results - "De Bruijne, Joep"

Emergence of Hepatitis C Virus Genotype 4: Phylogenetic Analysis Reveals Three Distinct Epidemiological Profiles by de Bruijne, Joep, Schinkel, Janke, Prins, Maria, Koekkoek, Sylvie M, Aronson, Sem J, van Ballegooijen, Marijn W, Reesink, Hendrik W, Molenkamp, Richard, van de Laar, Thijs J.W

“…Hepatitis C virus (HCV) genotype 4 (HCV-4) infection is considered to be difficult to treat and has become increasingly prevalent in European countries,…”
Get full text

Safety and Efficacy of 166Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study by Reinders, Margot TM, Van Erpecum, Karel J, Smits, Maarten LJ, Braat, Arthur JAT, De Bruijne, Joep, Bruijnen, Rutger, Sprengers, Dave, De Man, Robert A, Vegt, Erik, IJzermans, Jan NM, Moelker, Adriaan, Lam, Marnix GEH

“…The safety and efficacy of 166Ho radioembolization was first determined in the HEPAR and HEPAR II studies, which, however, excluded patients with…”
Get full text

Treatment for chronic hepatitis E virus infection: A systematic review and meta‐analysis by Gorris, Myrte, Lecq, Bernice M., Erpecum, Karel J., Bruijne, Joep

“…Hepatitis E virus infection can cause chronic hepatitis in immunocompromised patients with significant chance of progressive fibrosis and possibly cirrhosis…”
Get full text

Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C by Dik, Kathelijne, de Bruijne, Joep, Takkenberg, R. Bart, Roelofs, Joris J., Tempelmans, Marjan J., Dijkgraaf, Marcel G. W., Gelderblom, Huub C., Reesink, Henk W., Meijers, Joost C. M., Jansen, Peter L., Levi, Marcel

“…Aim:  There is considerable variation in liver fibrosis stage and progression to cirrhosis among patients with chronic hepatitis B (CHB) or C (CHC)…”
Get full text

90Y-/166Ho- ‘Radiation lobectomy’ for liver tumors induces abnormal morphology and impaired drainage of peritumor lymphatics by Andel, Daan, van den Bent, Lotte, Ernest Hendrik Lam, Marnix Gerard, Johannes Smits, Maarten Leonard, Molenaar, Isaac Quintus, de Bruijne, Joep, Laclé, Miangela Marie, Kranenburg, Onno, Max Borel Rinkes, Inne Hildbrand, Hagendoorn, Jeroen

“…High-dose unilobar radioembolization, or ‘radiation lobectomy’ (RL), is an induction therapy that achieves contralateral future liver remnant hypertrophy while…”
Get full text

Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature by Braat, Manon N G J A, Ebbers, Sander C, Alsultan, Ahmed A, Neek, Atal O, Bruijnen, Rutger C G, Smits, Maarten L J, de Bruijne, Joep, Lam, Marnix G E H, Braat, Arthur J A T

“…Trans-arterial radioembolization is a well-studied tumoricidal treatment for liver malignancies; however, consensus and evidence regarding periprocedural…”
Get full text

Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir by Thomas, Xiomara V, de Bruijne, Joep, Sullivan, James C, Kieffer, Tara L, Ho, Cynthia K Y, Rebers, Sjoerd P, de Vries, Michel, Reesink, Hendrik W, Weegink, Christine J, Molenkamp, Richard, Schinkel, Janke

“…Telaprevir, a hepatitis C virus NS3/4A protease inhibitor has significantly improved sustained viral response rates when given in combination with pegylated…”
Get full text

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients by van der Ree, Meike H., van der Meer, Adriaan J., de Bruijne, Joep, Maan, Raoel, van Vliet, Andre, Welzel, Tania M., Zeuzem, Stefan, Lawitz, Eric J., Rodriguez-Torres, Maribel, Kupcova, Viera, Wiercinska-Drapalo, Alcija, Hodges, Michael R., Janssen, Harry L.A., Reesink, Hendrik W.

“…•We present the long-term safety and efficacy outcome of patients treated with anti-miR therapy.•No long-term safety issues were observed among…”
Get full text

TOP-401-YI Improvement of liver stiffness during nucleo (s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk by Patmore, Lesley A., Liang, Yan, Kilany, Mai, d'Almeida, Arno Furquim, Wong, Vincent Wai-Sun, Vanwolleghem, Thomas, Honkoop, Pieter, Blokzijl, Hans, Koc, Ozgur, Janssen, Harry L.A., Kramer, Matthijs, de Bruijne, Joep, Kaewdech, A., de Man, Robert A., Takkenberg, R. Bart, Wong, Grace Lai-Hung, Feld, Jordan J., Sonneveld, Milan J.

Get full text

Therapeutic window for ribavirin therapy in transplant recipients with chronic hepatitis E virus infection by Mulder, Midas, De Man, Robert, Kamar, Nassim, Durmaz, Gülcan, de Bruijne, Joep, Vanwolleghem, Thomas, Van der Eijk, Annemiek, Van Gelder, Teun, Hesselink, Dennis, De Winter, Brenda

Get full text

SAT407 - Therapeutic window for ribavirin therapy in transplant recipients with chronic hepatitis E virus infection by Mulder, Midas, De Man, Robert, Kamar, Nassim, Durmaz, Gülcan, de Bruijne, Joep, Vanwolleghem, Thomas, Van der Eijk, Annemiek, Van Gelder, Teun, Hesselink, Dennis, De Winter, Brenda

Get full text

Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe by Patmore, Lesley A., van Eekhout, Kirsi M.A., Buti, Maria, Koc, Özgur.M., Agarwal, Kosh, de Knegt, Rob J., Janssen, Harry L.A., van der Valk, Marc, Lieveld, Faydra I., Hansen, Bettina E., Kramer, Matthijs, de Bruijne, Joep, Claassen, Mark A.A., Smit, Colette, de Man, Rob A., Takkenberg, Bart, Carey, Ivana, Sonneveld, Milan J.

“…Sub-Saharan African (SSA) ethnicity has been associated with a higher risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis B in…”
Get full text

Holmium-166 radioembolisation dosimetry in HCC by Reinders, Margot T M, Braat, Arthur J A T, van Erpecum, Karel J, de Bruijne, Joep, Bruijnen, Rutger C G, Sprengers, Dave, de Man, Rob, Vegt, Erik, IJzermans, Jan N M, Elias, Sjoerd G, Lam, Marnix G E H, Smits, Maarten L J

“…To evaluate dosimetry, dose-response and dose-toxicity relationships for holmium-166 ( Ho) radioembolisation in patients with hepatocellular carcinoma (HCC)…”
Get full text

Safety and Efficacy of 166 Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study by Reinders, Margot T M, van Erpecum, Karel J, Smits, Maarten L J, Braat, Arthur J A T, Bruijne, Joep de, Bruijnen, Rutger, Sprengers, Dave, Man, Robert A de, Vegt, Erik, IJzermans, Jan N M, Moelker, Adriaan, Lam, Marnix G E H

“…The safety and efficacy of Ho radioembolization was first determined in the HEPAR and HEPAR II studies, which, however, excluded patients with hepatocellular…”
Get full text

Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation by Smits, Maarten L. J., Bruijnen, Rutger C. G., Tetteroo, Philip, Vonken, Evert-jan P. A., Meijerink, Martijn R., Hagendoorn, Jeroen, de Bruijne, Joep, Prevoo, Warner

“…Purpose We present a technique that combines Hepatic Arteriography with C-arm CT-Guided Ablation (HepACAGA) to improve tumor visualization, navigation and…”
Get full text

Systematic review with meta‐analysis: Branched‐chain amino acid supplementation in liver disease by Dijk, Anne M., Bruins Slot, Alexandra S., Portincasa, Piero, Siegerink, Sebastiaan N., Chargi, Najiba, Verstraete, Carina J. R., Bruijne, Joep, Vleggaar, Frank P., Erpecum, Karel J.

“…Background Dietary supplementation with branched‐chain amino acids (BCAA) is often used in cirrhotic patients to improve nutritional status. We wanted to…”
Get full text

Nutritional status in patients with hepatocellular carcinoma: Potential relevance for clinical outcome by van Dijk, Anne M., Coppens, Bart J.P., van Beers, Maartje A., Bruins Slot, Alexandra S., Verstraete, Carina J.R., de Bruijne, Joep, Vleggaar, Frank P., van Erpecum, Karel J.

“…BACKGROUNDImpaired nutritional status is a risk factor for unfavorable outcome in cirrhosis. METHODSIn this prospective cohort study in hepatocellular…”
Get full text

Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy by Lenz, Oliver, de Bruijne, Joep, Vijgen, Leen, Verbinnen, Thierry, Weegink, Christine, Van Marck, Herwig, Vandenbroucke, Ina, Peeters, Monika, Simmen, Kenneth, Fanning, Greg, Verloes, Rene, Picchio, Gaston, Reesink, Hendrik

“…In the TMC435-C101 study, 6 patients infected with hepatitis C virus genotype 1 were treated with the protease inhibitor TMC435 (200 mg once daily) as…”
Get full text

Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol by Andel, Daan, Lam, Marnix G. E. H, de Bruijne, Joep, Smits, Maarten L. J, Braat, Arthur J. A. T, Moelker, Adriaan, Vegt, Erik, Ruiter, Simeon J. S, Noordzij, Walter, Grazi, Gianluca, Vallati, Giulio E, Bennink, Roel J, van Delden, Otto M, Kranenburg, Onno W, Ijzermans, Jan N. M, Nijkamp, Maarten W, Erdmann, Joris I, Sciuto, Rosa, Hagendoorn, Jeroen, Borel Rinkes, Inne H. M

“…Background High dose unilobar radioembolization (also termed 'radiation lobectomy')--the transarterial unilobar infusion of radioactive microspheres as a means…”
Get full text

Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection by Mulder, Midas B., Man, Robert A., Kamar, Nassim, Durmaz, Gűlcan, Bruijne, Joep, Vanwolleghem, Thomas, Izopet, Jacques, Gandia, Peggy, Eijk, Annemiek A., Gelder, Teun, Hesselink, Dennis A., Winter, Brenda C.M.

“…The aim of this study was to define the therapeutic range for ribavirin (RBV) in transplant recipients with chronic hepatitis E virus (HEV) infection. In this…”
Get full text